Vorinostat increases expression of functional norepinephrine transporter in neuroblastoma in vitro and in vivo model systems by More Swati S, Itsara Melissa, Yang Xiaodong, Geier Ethan G, Tadano Michelle K, Seo Youngho, Vanbrocklin Henry F, Weiss William A, Sabine Mueller, Haas-Kogan Daphne A, Dubois Steven G, Matthay Katherine K, Giacomini Kathleen M in Clinical cancer research : an official journal of the American Association for Cancer Research (2011). PubMed

Abstract

PURPOSE: Histone deacetylase (HDAC) inhibition causes transcriptional activation or repression of several genes that in turn can influence the biodistribution of other chemotherapeutic agents. Here, we hypothesize that the combination of vorinostat, a HDAC inhibitor, with 131I-metaiodobenzylguanidine (MIBG) would lead to preferential accumulation of the latter in neuroblastoma (NB) tumors via increased expression of the human norepinephrine transporter (NET). EXPERIMENTAL DESIGN: In vitro and in vivo experiments examined the effect of vorinostat on the expression of NET, an uptake transporter for 131I-MIBG. Human NB cell lines (Kelly and SH-SY-5Y) and NB1691luc mouse xenografts were employed. The upregulated NET protein was characterized for its effect on 123I-MIBG biodistribution.RESULTS: Preincubation of NB cell lines, Kelly and SH-SY-5Y, with vorinostat caused dose-dependent increases in NET mRNA and protein levels. Accompanying this was a corresponding dose-dependent increase in MIBG uptake in NB cell lines. Four-fold and 2.5 fold increases were observed in Kelly and SH-SY-5Y cells, respectively, pre-treated with vorinostat in comparison to untreated cells. Similarly, NB xenografts, created by intravenous tail vein injection of NB1691-luc, and harvested from nude mice livers treated with vorinostat (150 mg/kg i.p.) showed substantial increases in NET protein expression. Maximal effect of vorinostat pretreatment in NB xenografts on 123I-MIBG biodistribution was observed in tumors that exhibited enhanced uptake in vorinostat treated (0.062 ± 0.011 µCi/(mg tissue-dose injected)) versus untreated mice (0.022 ± 0.003 µCi/(mg tissue-dose injected); p < 0.05). CONCLUSIONS: The results of our study provide preclinical evidence that vorinostat treatment can enhance NB therapy with 131I-MIBG.

[ hide abstract ]

Discussed In Paper